This company has been marked as potentially delisted and may not be actively trading. (BIOA) (BIOA) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipTrendsBuy This Stock BIOA vs. ABUS, TRVI, PHAR, ORGO, CRMD, CAPR, BCYC, KROS, AKBA, and COGTShould you be buying (BIOA) stock or one of its competitors? The main competitors of (BIOA) include Arbutus Biopharma (ABUS), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Organogenesis (ORGO), CorMedix (CRMD), Capricor Therapeutics (CAPR), Bicycle Therapeutics (BCYC), Keros Therapeutics (KROS), Akebia Therapeutics (AKBA), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical preparations" industry. (BIOA) vs. Arbutus Biopharma Trevi Therapeutics Pharming Group Organogenesis CorMedix Capricor Therapeutics Bicycle Therapeutics Keros Therapeutics Akebia Therapeutics Cogent Biosciences (BIOA) (NYSE:BIOA) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Does the MarketBeat Community believe in BIOA or ABUS? Arbutus Biopharma received 145 more outperform votes than (BIOA) when rated by MarketBeat users. However, 72.03% of users gave (BIOA) an outperform vote while only 70.66% of users gave Arbutus Biopharma an outperform vote. CompanyUnderperformOutperform(BIOA)Outperform Votes29172.03% Underperform Votes11327.97% Arbutus BiopharmaOutperform Votes43670.66% Underperform Votes18129.34% Is BIOA or ABUS more profitable? (BIOA) has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,137.65%. (BIOA)'s return on equity of 0.00% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets (BIOA)N/A N/A N/A Arbutus Biopharma -1,137.65%-68.18%-51.55% Does the media prefer BIOA or ABUS? In the previous week, Arbutus Biopharma had 3 more articles in the media than (BIOA). MarketBeat recorded 3 mentions for Arbutus Biopharma and 0 mentions for (BIOA). Arbutus Biopharma's average media sentiment score of 1.35 beat (BIOA)'s score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Overall Sentiment (BIOA) Neutral Arbutus Biopharma Positive Do analysts rate BIOA or ABUS? (BIOA) currently has a consensus price target of $5.67, suggesting a potential upside of 35.73%. Arbutus Biopharma has a consensus price target of $5.50, suggesting a potential upside of 53.20%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Arbutus Biopharma is more favorable than (BIOA).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score (BIOA) 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of BIOA or ABUS? 43.8% of Arbutus Biopharma shares are held by institutional investors. 20.3% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, BIOA or ABUS? (BIOA) has higher earnings, but lower revenue than Arbutus Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio(BIOA)N/AN/AN/AN/AN/AArbutus Biopharma$6.17M111.39-$72.85M-$0.38-9.45 SummaryArbutus Biopharma beats (BIOA) on 9 of the 13 factors compared between the two stocks. Get (BIOA) News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOA vs. The Competition Export to ExcelMetric(BIOA)Pharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$161.32M$6.85B$5.56B$19.21BDividend YieldN/A2.95%5.09%4.00%P/E RatioN/A7.4422.6833.45Price / SalesN/A257.63404.2829.18Price / CashN/A65.8538.1817.52Price / BookN/A6.576.794.55Net IncomeN/A$143.14M$3.22B$1.02B (BIOA) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOA(BIOA)N/A$4.18-10.0%$5.67+35.7%+32,517.2%$161.32MN/A0.00N/AABUSArbutus Biopharma2.0782 of 5 stars$3.34+1.5%$5.50+64.7%+34.0%$639.54M$6.17M-7.7790News CoverageTRVITrevi Therapeutics3.6202 of 5 stars$6.59+1.9%$17.56+166.5%+132.2%$637.13MN/A-14.9820Upcoming EarningsNews CoveragePositive NewsPHARPharming Group2.7412 of 5 stars$8.75+2.8%$30.00+242.9%-9.8%$595.27M$297.20M-33.65280Upcoming EarningsShort Interest ↓Positive NewsGap UpORGOOrganogenesis2.7576 of 5 stars$4.67+2.4%$5.50+17.8%+112.0%$592.29M$482.04M-77.83950Upcoming EarningsNews CoveragePositive NewsCRMDCorMedix2.5388 of 5 stars$9.06-0.4%$14.50+60.0%+74.7%$590.55M$43.47M-11.1930Upcoming EarningsCAPRCapricor Therapeutics1.7314 of 5 stars$12.83-1.5%$34.50+168.9%+126.3%$586.04M$22.27M-12.10N/ANews CoverageBCYCBicycle Therapeutics3.5309 of 5 stars$8.40-0.2%$29.14+246.9%-62.3%$581.30M$35.28M-2.55240Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageKROSKeros Therapeutics3.1546 of 5 stars$14.26+0.4%$40.33+182.8%-74.3%$578.41M$3.55M-2.74100Upcoming EarningsNews CoveragePositive NewsAKBAAkebia Therapeutics4.1037 of 5 stars$2.43+2.1%$6.63+172.6%+88.5%$574.04M$160.18M-10.56430Upcoming EarningsAnalyst UpgradeAnalyst RevisionNews CoveragePositive NewsCOGTCogent Biosciences2.191 of 5 stars$4.91+5.8%$14.43+193.9%-19.5%$559.03MN/A-1.9880Upcoming EarningsOptions VolumeAnalyst Revision Related Companies and Tools Related Companies Arbutus Biopharma Alternatives Trevi Therapeutics Alternatives Pharming Group Alternatives Organogenesis Alternatives CorMedix Alternatives Capricor Therapeutics Alternatives Bicycle Therapeutics Alternatives Keros Therapeutics Alternatives Akebia Therapeutics Alternatives Cogent Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BIOA) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (BIOA) Please log in to your account or sign up in order to add this asset to your watchlist. Share (BIOA) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
